Kambara, Misa
Yanagisawa, Keiko
Tanaka, Sayoko
Suzuki, Tomoko
Babazono, Tetsuya
Article History
Received: 8 December 2017
Accepted: 13 August 2018
First Online: 21 August 2018
Compliance with ethical standards
:
: Author Babazono received lecture fees from MSD K.K., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Phama Ltd., Takeda Pharma Ltd., Mitsubishi Tanabe Pharma Corp, Astellas Pharma Inc., Chugai Pharma Manufacturing Co., Ltd., Boehringer Ingerheim, Astra Zeneca K.K., Otsuka Pharmacuetical Co., Ltd., Kowa Shinyaku Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Daiichi Sankyo Co., Ltd., and research grants from Novartis Phama K.K., Astellas Pharma Inc., Pfizer Japan Inc., Chugai Pharma Manufacturing Co., Ltd., Boehringer Ingerheim, Astra Zeneca K.K., Kyowa Hakko Kirin Co., Ltd., Alcon, Otsuka Pharmacuetical Co., Ltd., Nipro; Eli Lilly Japan K.K., Kowa Shinyaku Co., Ltd., Eizai Co., Ltd., Takeda Pharma Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono pharmaceutical Co., Novo Nordisk Phama Ltd., Terumo Corp., Sumitomo Dainippon Pharma Co., Ltd., and Daiichi Sankyo Co., Ltd. Other authors declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study. This study was approved by the Ethical Committee of Tokyo Women’s Medical University School of Medicine (Approval No. 3920R, approval date: 2 June 2017).